Source: Reuters (Africa)
By: Hirschler, Ben
An experimental tuberculosis vaccine could undergo “proof of concept” tests in Kenya, South Africa, and India next year. The launch of a mid-stage Phase IIb clinical study would depend in part on successful initial tests of the GlaxoSmithKline vaccine candidate. GSK has partnered with the U.S.-based nonprofit biotech group Aeras to develop the product that contains its proprietary antigen M72 and the adjuvant AS01E, which includes an ingredient licensed from Agenus unit Antigenics. The product is designed to be used in addition to the currently available TB vaccine, Bacille Calmette-Guerin (BCG); the majority of infections and deaths result from pulmonary TB, which is not prevented by BCG.